Source: Annual Congress 2002 - Asthma - Therapy and management -2
Disease area: Airway diseases

Abstract

To evaluate patient well-being during treatment of acute severe asthma. During a 4-hour investigation, 88 emergency room patients (mean age 44 yr, mean FEV₁ 44% pred.) were randomized to either formoterol 18 μg (Oxis® Turbuhaler) or salbutamol 800 μg pMDI plus spacer 3 times over the first hour in a double-blind, double-dummy study. The Acute Asthma Quality of Life Questionnaire (Acute AQLQ) and a symptom scale were administered before and 4 hours after treatment. Acute AQLQ includes 11 items with responses from 1 to 7 (7=no impairment). Symptoms were scored on a 0 to 100 visual analog scale (VAS, 100=severe symptoms). Acute AQLQ overall scores increased from 2.7 to 5.9 and 2.5 to 5.7 following treatment with formoterol and salbutamol, respectively. VAS scores reduced from 64 in both groups to 9 and 13, respectively. All changes were statistically significant but there was no difference between the groups for Acute AQLQ (p=0.41) or VAS (p=0.32). In patients with acute severe asthma Oxis® Turbuhaler 54 μg and salbutamol 240 μg by pMDI plus spacer had a similar effect on patients' well-being.

Rating:

Share or cite this content

Citations should be made in the following way:
E. F. Juniper, S. Charoenratanakul, W. Boonsawat, A. C. Mörk, E. Slåhl (Hamilton, Canada; Bangkok, Thailand; Lund, Sweden). Treatment of acute severe asthma with formoterol Turbuhaler provides a similar effect on patients' well-being as salbutamol by pMDI plus spacer. Eur Respir J 2002; 20: Suppl. 38, 410

Member's Comments

No comment yet.

Related content which might interest you: Formoterol turbuhaler as a rescue therapy was as effective and safe as salbutamol by pMDI and spacer in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002 Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002 Addition of formoterol Turbuhaler® to budesonide Turbuhaler® increases the time to first severe exacerbation in long-term treatment of mild asthma: results from OPTIMA Source: Eur Respir J 2001; 18: Suppl. 33, 517s Year: 2001 Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 209s Year: 2006 Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002 Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007 Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007 Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005 Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008 Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Early and sustained benefits of budesonide and formoterol in a single inhaler vs fluticasone in moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005 Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone Source: Eur Respir J 2001; 18: 262-268 Year: 2001 Addition of formoterol Turbuhaler® to budesonide Turbuhaler® is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial Source: Eur Respir J 2001; 18: Suppl. 33, 330s Year: 2001 Bronchodilator response to salbutamol administered through metered-dose inhaler plus spacer or dry-powder inhaler in asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001 The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005 Comparison of HFA fluticasone-formoterol combination pressurized meter dose inhaler (pMDI) and HFA budesonide-formoterol combination pMDI in patients with moderate to severe persistent asthma Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001 Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001 Comparison of bronchodilator effect of salbutamol delivered via MDI + spacer and DPI in children with asthma Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases Year: 2012